StockNews.com began coverage on shares of Milestone Scientific (NYSE:MLSS – Free Report) in a report released on Friday morning. The firm issued a hold rating on the stock.
Separately, Benchmark started coverage on Milestone Scientific in a research report on Thursday, October 10th. They issued a “speculative buy” rating and a $1.25 target price for the company.
Read Our Latest Research Report on MLSS
Milestone Scientific Stock Down 2.1 %
Milestone Scientific (NYSE:MLSS – Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%. The company had revenue of $1.85 million for the quarter.
Insider Buying and Selling
In related news, Director Leonard Osser sold 141,913 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $0.95, for a total transaction of $134,817.35. Following the sale, the director now owns 4,602,506 shares of the company’s stock, valued at $4,372,380.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 251,106 shares of company stock worth $236,451 in the last three months. 24.75% of the stock is owned by corporate insiders.
Milestone Scientific Company Profile
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
See Also
- Five stocks we like better than Milestone Scientific
- Using the MarketBeat Dividend Tax Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a SEC Filing?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Invest in Blue Chip Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Milestone Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific and related companies with MarketBeat.com's FREE daily email newsletter.